Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

emerging markets

China flag thumb

UK-US risk investigator team arrested in China

Corporate investigators with possible links to GSK detained

Novartis building

Novartis drawn into Chinese corruption probe

Former sales rep files bribery complaint about Sandostatin LAR prescribing practices

China flag thumb

China’s bribery probe goes national

Expands investigation that already affects GSK, Sanofi, Lilly, AZ, Lundbeck, Novo and UCB

China flag thumb

Sanofi drawn into Chinese corruption probe

Joins GSK, UCB, AZ , Lilly, Novo and Lundbeck as companies under scrutiny

- PMLiVE

The MISTs of time – new emerging markets

As the BRIC foundations become firmly established, where next – and how soon – for those pharma companies seeking to exploit the developing markets?

China flag thumb

Sanofi and Lilly also visited by Chinese authorities

Follows GSK bribery allegations

- PMLiVE

Building and delivering market access capabilities in emerging markets

Local skills gaps must be addressed if the potential of the BRIC countries is to be realised

- PMLiVE

GSK replaces China head as bribery probe rolls on

Herve Gisserot takes over from Mark Reilly

- PMLiVE

Witty says Chinese bribery probe will impact GSK

CEO says company’s performance in China will be affected

- PMLiVE

All eyes on pharma in Brazil

With a large population, a growing economy and a well-established healthcare system, Brazil is high on the list for most companies looking to expand into emerging markets.

China flag thumb

AstraZeneca and UCB drawn into Chinese investigations

Follows country’s clampdown on GSK bribery

- PMLiVE

Infographic: Pharma investment in Indonesia

Pharma deals in the region since the introduction of Decree 1010 to force companies to manufacture products locally

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links